Thiazole isomers as potential ALK5 inhibitors alleviate P2X7R-mediated inflammation during liver fibrosis

Area of Science:

• Hepatology
• Pharmacology
• Molecular Biology

Background:

• Liver fibrosis is a precursor to cirrhosis and liver cancer.
• Molecular mechanisms driving liver fibrosis require further elucidation for precision therapy development.
• Activin receptor like kinase 5 (ALK5/TGF-βRI) is a key therapeutic target for antifibrotic agents.

Purpose of the Study:

• To design and synthesize novel thiazole derivatives targeting ALK5 for hepatic fibrosis.
• To evaluate the antifibrotic and anti-inflammatory effects of J-1155 and J-1156.
• To investigate the molecular mechanisms underlying the therapeutic action of these compounds.

Main Methods:

• Synthesis of two novel thiazole derivatives, J-1155 and J-1156, with enantiomeric amino acid moieties.
• Assessment of antifibrotic and anti-inflammatory efficacy in a hepatic fibrosis model.
• Analysis of dual inhibition of the TGF-β/Smad signaling pathway and P2X7R-NLRP3 inflammasome axis.

Main Results:

• Both J-1155 and J-1156 effectively attenuated hepatic fibrosis and inflammation.
• Compounds demonstrated dual inhibition of the TGF-β/Smad pathway and P2X7R-NLRP3 inflammasome.
• J-1156 showed superior overall antifibrotic efficacy, while J-1155 exhibited better Smurf2 modulation.

Conclusions:

• J-1155 and J-1156 are promising dual therapeutic agents for hepatic fibrosis.
• Targeting ALK5 via these novel compounds offers a potential precision therapy approach.
• The dual inhibition mechanism provides a novel strategy for managing liver fibrosis progression.